All In Biotech

Drug Trial Radar · NCT00992459

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)

Last checked: Nov 20, 2026Latest source record: Jul 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

46

Actual

Start

Oct 2009

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, active-controlled, double-blind, cross-over study designed to enroll subjects with UCDs who are being treated with NaPBA.

Conditions

  • Urea Cycle Disorders

Interventions

  • HPN-100Drug

    HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.

  • Buphenyl (NaPBA)Drug

    Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Primary Endpoint Was the 24-hour Area Under the Curve for Blood Ammonia (NH324-hour AUC) on Days 14 and 28.Time frame: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Long Beach Memorial

    Long Beach, California

  • UCLA

    Los Angeles, California

  • Stanford University

    Stanford, California

  • Denver Children's Hospital

    Aurora, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • University of Florida

    Gainesville, Florida

  • University of Iowa

    Iowa City, Iowa

  • Maine Medical Center

    Portland, Maine

  • SNBL-Clinical Pharmacology Center

    Baltimore, Maryland

  • Tufts-New England Medical Center

    Boston, Massachusetts

  • University of Minnesota Medical Center

    Minneapolis, Minnesota

  • Mount Sinai School of Medicine

    New York, New York

  • Westchester Medical Center

    Valhalla, New York

  • University Hospitals Case Medical Center

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.